Earnings ·
MBX Biosciences reported second quarter 2026 financial results, posting a net loss of $37.1 million on R&D expenses of…
MBXMBX Biosciences, Inc.
MBX Biosciences reported second quarter 2026 financial results, posting a net loss of $37.1 million on R&D expenses of $31.0 million and G&A expenses of $9.9 million. The company holds $418.6 million in cash and investments, sufficient to fund operations into 2029. Key operational updates include the initiation of recruitment for the Phase 3 oPTimize trial of canvuparatide for chronic hypoparathyroidism and preliminary Phase 1 data for MBX 4291 showing a mean weight loss of 7% at eight weeks. Additionally, MBX nominated MBX 6180 as its lead GLP-1/GIP/GCG triple agonist development candidate for obesity. Steve Hoerter was appointed Chairman and CEO, succeeding Kent Hawryluk, while John Smither became CFO. The company operates in the biopharmaceutical industry, developing precision peptide therapies for endocrine and metabolic disorders.